Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, announced the pricing of its upsized initial public offering of 8,400,000 shares of common stock at a public offering price of $16.00 per share.
July 15, 2021
· 2 min read